Pakistan Science Abstracts
Article details & metrics
No Detail Found!!
Bioactive peptides as innovative therapies for lifestyle-related diseases
Author(s):
1. Umar Farooq: Depatment of Human Nutrition & Dietetics, MNS University of Agriculture, Multan, Pakistan
2. Smara Qaisar Alvi: Depatment of Human Nutrition & Dietetics, MNS University of Agriculture, Multan, Pakistan
3. Umrah Zafar: Depatment of Human Nutrition & Dietetics, MNS University of Agriculture, Multan, Pakistan
Abstract:
Lifestyle-related diseases are a major issue in the twenty-first century, with millions of people dying each year as a result of lifestyle choices and associated complications like diabetes, obesity, hypercholesterolemia and hypertension. Although synthetic drugs have been shown to be highly effective in treating these conditions, their safety remains a concern. Natural alternatives to drugs, such as food-derived peptides, are currently being investigated for the prevention and treatment of lifestyle-related complications. Peptides are nascent fragments of primary protein sequences that can provide health benefits in addition to nutritional benefits. Bioactive peptides may be able to prevent obesity by controlling adipocyte differentiation and lipase activity. In light of their ability to inhibit the enzymatic activity of DPP-IV, a-glucosidase and a-amylase, bioactive peptides are useful as drugs for type 2 diabetes. Furthermore, bioactive peptides can compete with angiotensin-converting enzymes, resulting in antihypertensive effects. Bioactive peptides have the potential to lower cholesterol by inhibiting cholesterol metabolic pathways and cholesterol synthesis. Whey protein, alactalbumin, and lactoferrin were found to be anti-obesity in an animal study. Overweight subjects who consumed 300 mg of lactoferrin daily for 8 weeks saw significant reductions in visceral fat, body weight, and BMI. As peptide discovery technology advances, more alternative avenues for treating complications, particularly obesity and type 2 diabetes, should be identified. In vivo and clinical trials have less data than in vitro studies, so this area needs to be prioritized. Furthermore, strategies for achieving peptide stability and targeted delivery via micro- and nano-conjugation must be prioritized. Moreover, clinical trials are required for production sequences and regulatory standards should be geared towards commercialization.
Page(s): 49-49
DOI: DOI not available
Published: Journal: Abstract Book on International Conference on Food and Applied Sciences (ICFAS-23) 3-5 August 23, Volume: 0, Issue: 0, Year: 2023
Keywords:
Obesity , Antihypertensive , Type 2 diabetes , bioactive peptides , micro and nano conjugation
References:
References are not available for this document.
Citations
Citations are not available for this document.
0

Citations

0

Downloads

103

Views